The main text of the study details the experiments conducted to understand the role of IL-24 in AD-like conditions. It describes the methods used, including single-cell RNA sequencing, and the animal models employed to mimic AD. The findings indicate that MRSA infection leads to increased IL-24 in keratinocytes, which in turn heightens type 2 immune responses and worsens AD symptoms.
Mirum expands rare disease portfolio with digestive disorder drugs – Pharmaceutical Technology
Mirum Therapeutics acquired two bile disorder drug products from Travere Therapeutics. Credit: peakSTOCK via Getty Images. California-based biotech Mirum Therapeutics has announced the completion of